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RESPONSIVENESS OF HUMAN T LYMPHOCYTES TO 
BACTERIAL SUPERANTIGENS PRESENTED BY 
CULTURED RHEUMATOID ARTHRITIS SYNOVIOCYTES 
CARLENE TSAI, LUIS A. DIAZ, JR., NORA G. SINGER, LAN LAN LI, ANITA H. KIRSCH, 
RAJ MITRA, BRIAN J. NICKOLOFF, LESLIE J. CROFFORD, and DAVID A. FOX 
Objective. Type B fibroblastic synoviocytes are 
abundant in inflamed joints of patients with rheumatoid 
arthritis (RA), and can secrete cytokines and other 
mediators of inflammation. The aim of this study was 
to determine whether cell lines derived from RA type 
B synoviocytes could also serve as accessory cells for T 
lymphocyte activation. 
Methods. Cells from RA synoviocyte lines, with 
or without preculture in interferon- y (IFNy), were 
cultured with purified peripheral blood T cells, in the 
presence or absence of superantigens or other accessory 
cell-dependent T cell mitogens. T cell proliferation was 
measured by thymidine incorporation, and synoviocyte 
surface markers were analyzed by flow cytometry. 
Resuh. RA type B synoviocyte lines were potent 
accessory cells for T cell responses to bacterial super- 
antigens or lectins, and direct cell-cell contact was 
required. Preculture in IFN y augmented synoviocyte 
expression of major histocompatibility complex (MHC) 
class II molecules and of ligands for some T cell costim- 
ulatory receptors, but synoviocyte accessory cell func- 
tion was evident even in the absence of IFNy. Blocking 
studies using monoclonal antibodies supported the no- 
tion of a role for CD2, CDlldCD18 and MHC class I1 
molecules in synoviocyte-dependent T cell activation. 
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Monoclonal antibodies against IFN y, interleukin-IS 
(IL-lB, IL-6, IL-8, and tumor necrosis factor a failed 
to block the T cell proliferative responses, but anti-IL-2 
was strongly inhibitory. 
Conclusion. Cultured RA type B synoviocytes 
can perform some of the functions of professional 
antigen-presenting cells. If such cells have similar prop- 
erties in vivo, they may be important partkipants in 
activation of immune responses, in addition to their 
previously described synthetic and proinflammatory 
roles. If RA synovial tissue T cells, like normal peri- 
pheral blood T cells, can respond to superantigens 
presented by synoviocytes, this interaction could be 
important in the pathogenesis of RA. 
Rheumatoid arthritis (RA) is an autoimmune 
disease characterized by proliferation of synovio- 
cytes, persistent inflammation of the synovium, and 
tissue destruction. Synovial tissue contains at least 2 
distinct populations of cells, which have been termed 
macrophage-like (type A) and fibroblast-like (type B) 
synoviocytes (1). Local proliferation of type B syno- 
viocytes contributes substantially to the synovial hy- 
perplasia that is characteristic of RA (2). Synthetic 
functions of type B synoviocytes, including secretion 
of hyaluronic acid and collagen, have been well doc- 
umented (3). These cells also contribute to inflamma- 
tory responses, by releasing substances such as pros- 
taglandins, metalloproteinases, and cytokines, which 
regulate cellular function within the synovial compart- 
ment and cause tissue damage. These processes are 
regulated by a variety of cytokines and cytokine 
inhibitors, acting individually, synergistically, or 
antagonistically (4-1 l) ,  as well as by mediators of 
inflammation, such as kinins (12). 
Although some functions of synoviocytes are 
mediated by secreted products, other functions may 
require direct interaction with cells of the immune 
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system that migrate to the synovium during inflamma- 
tion. In order to support antigen presentation to CD4+ 
T cells, accessory cells must express major histocom- 
patibility complex (MHC) class 11 molecules as well 
as other, costimulatory molecules. In several reports, 
type B synoviocytes from patients with RA have 
been shown to express MHC class 11, intercellular 
adhesion molecule 1 (ICAM-1) (CD54), vascular cell 
adhesion molecule I (VCAM-1) (CDlM), integrins, and 
other molecules involved in cell-cell interaction within 
the inflamed joint or ex vivo (4,13-21). MHC class I1 
determinants are induced on cultured type B synovio- 
cytes from RA patients in the presence of interferon-y 
(IFNy) (4). In addition, IFNy and other cytokines have 
been reported to enhance ICAM-1 and VCAM-1 ex- 
pression (16,18,19). Anti-VCAM-1 antibodies have 
been found to block the binding of the Jurkat T cell line 
to type B synoviocytes (16). 
Despite this finding that synoviocytes express 
ligands for T lymphocyte surface glycoproteins, there 
is as yet little direct evidence for a role of these cells in 
the afferent arm of the immune responses as antigen- 
presenting cells. Recent studies demonstrated that the 
superantigen (SAg) staphylococcal enterotoxin A 
(SEA) induces MHC class 11-positive type B synovio- 
cytes to secrete interleukin-6 (IL-6) and IL-8 (22). 
Since it has been suggested that SAg may be involved 
in the pathogenesis of RA (23,24), we investigated the 
interaction of cultured type B synoviocytes derived 
from RA patients and peripheral T lymphocytes in the 
presence of staphylococcal SAg. We demonstrated 
that synoviocytes can act as accessory cells in SAg 
and lectin responses, and provide the necessary co- 
stimulatory signals to support the activation and pro- 
liferation of peripheral blood T lymphocytes. Further- 
more, interaction between synoviocytes and T 
lymphocytes was shown to require direct cell-cell 
contact and to involve certain costimulatory structures 
in addition to MHC class I1 proteins. These data suggest 
that type B synoviocytes not only possess synthetic, 
secretory, and proinflammatory capabilities, but can 
also support T cell activation. Such interactions be- 
tween synoviocytes, SAg, and T lymphocytes could 
contribute to the pathophysiology of RA. 
MATERIALS AND METHODS 
Monoclonal antibodies. Monoclonal antibodies 
(MAb), MHC class 11, CD2, CD4, CDlla (lymphocyte 
functio*associated antigen 1 [LFA-I]), CDl lb (MO-l), 
CD14 (MO-2), CD50 (ICAM-3), CD54 (ICAM-I), CD58 
(LFA-3), CD60, CD8O (B7-1/BBl), CD86, (B7-2, B70), 
CD98, CD102 (ICAM-2), CD106 (VCAM-l), 54-81 (ALCAM) 
IFNy, IL-lp, IL-2, IL-6, IL-8, and tumor necrosis factor a 
(TNFa), as well as isotype-matched control reagents, were 
used. The anti-CD14 and anti-CD16 MAb were generously 
provided by Dr. Rob Todd (University of Michigan). Anti- 
bodies to ICAM-1 and VCAM-1 were gifts from Dr. Yoji 
Shimizu (University of Michigan). Antibodies to ICAM-2 
and ICAM-3, and the 54-81 antibody were obtained from the 
Fifth Leukocyte Typing Workshop Blind Panel (25). Several 
antibodies were produced as previously described, i.e., 
anti-CD2 antibody UMCD2 (26), isotype control anti-von 
Willebrand factor (27), and anti-CD98 antibody UM7F8 (28). 
Antibody-producing hybridomas, anti-CD58 (TS 2/9.1.4.3.; 
I s , ) ,  anti-LFA-la(TS 1/22.1.1.13), and OKT3 (CRL 8001) 
were purchased from American Type Culture Collection 
(Rockville, MD). Anti-CD80/B7-1 (Ancell, Bayport, MN), 
anti-CD86/B7-2/B70 (Pharmigen, San Diego, CA), and neu- 
tralizing antibodies to human cytokines IL-1 p, IL-6 (Gibco 
BRL, Grand Island, NY), IL-2 (R & D Systems, Minneap- 
olis, MN), IL-8, and TNFa (Biosource International, Cama- 
rillo, CA) were purchased. A second anti-TNFa MAb 
termed cA2 (29) and an antibody to IFNy (B133.3.1) were 
generous gifts from Dr. James Woody (Centodor, Malvern, 
PA). All reagents were murine monoclonal antibodies ex- 
cept cA2 and B 133.3.1 (chimeric mousehuman monoclon- 
als) and antibodies to IL-1p and IL-6 (rabbit polyclonals). 
These reagents were used at a final concentration of 10 
pg/ml. 
For flow cytometric analysis, saturating dilutions of 
ascites fluid or 10 pg/ml of purified MAb were used. For 
inhibition of proliferative responses, antibodies were puri- 
fied by passage over protein A or protein G Sepharose beads 
and used at a final concentration of 10 pg/ml. 
Synoviocyte culture. Synovial specimens obtained at 
the time of total joint replacement from patients with RA 
were treated with 4 mg/ml collagenase (type I; Worthington 
Biochemical, Freehold, NJ) for 4 hours in Dulbecco’s mod- 
ified Eagle’s medium (DMEM) at 37°C in 5% C02. The 
dissociated cells were then centrifuged at SOOg, resuspended 
in DMEM supplemented with 10% fetal calf serum (FCS; 
Gibco BRL), 10% human AB serum (Biowhitaker, Walkers- 
ville, MD), penicillin (100 units/ml), and streptomycin (100 
pg/ml), and plated in 75-cm2 flasks. When the cells reached 
95% confluence, they were passaged at a dilution of 1:3 into 
175-mm2 flasks. The confluent adherent cells were split by 
gentle trypsinization (trypsinEDTA; Irvine Scientific, Walk- 
ersville, MD). Cells were used between the third and the 
twelfth passages. IFN y (Genentech, South San Francisco, 
CArtreated synoviocytes were precultured in 1 ,OOO units/ml 
IFN y for 48-72 hours before assay. 
T lymphocyte purification. Human peripheral blood 
mononuclear cells (PBMC) from healthy normal donors 
were separated by Ficoll-Hypaque (Sigma, St. Louis, MO) 
density gradient centrifugation. T lymphocytes were isolated 
from the PBMC by separating E+ rosette cells (T cells) and 
E- rosette cells, using sheep red blood cells. Macrophages 
were coated with MAb to CD14 and MHC class I1 mole- 
cules, and were depleted from the E+ rosette cells by 2 
rounds of panning with microselector flasks (Applied Im- 
mune Sciences, Santa Clara, CA). Depletion of accessory 
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Table 1. Flow cytometric analysis of non-IFN ytreated and IFN ytreated synoviocytes* 
Untreated synoviocytes IFN ytreated synoviocytes 
Passages Passages Passages Passages Passages Passages 
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* Cells were cultured in medium alone or supplemented with interferon-y (IFNy) as described in 
Materials and Methods. Cells were stained with antibodies to the surface markers indicated and 
analyzed by flow cytometry. Although late-passage non-IFN ytreated synoviocytes expressed inter- 
cellular adhesion molecule I (ICAM-I) and vascular cell adhesion molecule 1 (VCAM-I) at >50% 
fluorescence, expression of these molecules was upregulated significantly by IFNy Results shown 
are pooled data from synoviocyte lines derived from 3 different individuals. - = 4% staining; + = 
>5-20% staining; + + = >2&50% staining; + + + = >So% staining. LFA-3 = lymphocyte function- 
associated antigen 3; ND = not determined; MHC = major histocompatibility complex. 
t Recognizes a CD6 ligand termed ALCAM. 
cells from T lymphocyte preparations was monitored, and 
confirmed by lack of T cell proliferation with SEA, SEB, and 
Prolieration assays. SEA and SEB were purchased 
from Sigma, and phytohemagglutinin (PHA) from Munex 
Diagnostics (Atlanta, GA). Proliferation assays were per- 
formed in triplicate. T cells (5 X 104) purified as described 
above, were cultured in 96-well round-bottomed culture 
plates (Costar, Cambridge, MA). Synoviocytes (10’4 x 104) 
were added to the wells with OKT3, SEA, SEB, and PHA as 
stated in figure legends, in a final volume of 0.2 ml RPMI 
1640 with 10% FCS. Antibodies recognizing synoviocytes 
and T cells were used at the concentrations indicated. Plates 
were incubated for 4 days at 37°C with 5% CO,, pulsed for 
the final 18 hours of culture with 1 pCi/well of ’H-thymidine 
(ICN Biomedicals, Irvine, CA), harvested, and counted in a 
liquid scintillation counter (Pharmacia 1205/1204 BS Beta 
Counter). For proliferation assays, the results shown (mean 
5 SD) are from single experiments representative of at least 
3 similar experiments, using synoviocytes from different 
patients and T cells from different normal donors. 
Fluorescence-activated cell sorter (FACS) analysis. 
Flow cytometric analysis was performed using an Elite cell 
sorter (Coulter Electronics, Hialeah, FL). Positive cells 
were defined as those with fluorescence intensity beyond 
a threshold defined by the negative control (cells stained 
with isotype-matched nonspecific mouse Ig). Dead cells 
were excluded from analysis using forward and right-angle 
light scatter gating. Cell staining was measured in arbitrary 
units as the log fluorescence intensity and was recorded on 
a 3-log scale. For indirect immunofluorescence staining, 
phycoerythrin-conjugated second antibody was used to 
minimize background autofluorescence of synoviocytes 
(Molecular Probes, Eugene, OR). 
Effects of synoviocyte supernatants. Seventh-passage 
synoviocytes (5 x 10S/well), both IFNy-treated and non- 
IFNytreated, were placed in a 24-well plate and stimulated 
anti-CD3. 
with SEA for 12, 18, or 24 hours. The cells were placed at a 
final volume of 1 ml RPMI and 10% FCS. Aliquots of the 
supernatants (150 p) were placed in 96-well round-bottomed 
plates in triplicate, and 5 x lo4 T cells in 50 p.l were added to 
each well. Assays were performed in triplicate, and prolif- 
eration was measured as described above. 
RESULTS 
Synoviocyte expression of molecules necessary 
for T cell costimulation. FACS analysis was used to 
determine which molecules important for T cell co- 
Figure 1. Staphylococcal enterotoxin A (SEA) promotes T lymph* 
cyte binding to interferon- ytreated seventh-passage synoviocytes. 
A, Synoviocytes (5 x 16) were placed in 2Cwell plates and 
incubated for 4 days. B, Synoviocytes (5.0 x 10’) were cocultured 
with 2.5 x lo6 T lymphocytes for 2 days in 24-well plates. C, 
Synoviocytes (5.0 x 10’) and T lymphocytes (2.5 x 106) were 
cultured with SEA (100 ng/ml) for 2 days. Wells were washed twice 
with RPMI 164&10% fetal calf serum pior to photographing. (Orig- 
inal magnification ~ 2 0 0 . )  
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Figure 2. a, Function of synoviocytes as accessory cells for T cell responses to staphylococcal enteroxin A 
(SEA). Synoviocytes (1  .O x lo4; either interferon-y [IFN- y-treated or non-IFN-ytreated) and purified T 
cells (5  x 10") were added to the wells at culture initiation. Proliferation was determined as described in 
Materials and Methods, and is expressed as 3H-thymidine ([3H]-TdR) incorporation. In the presence of SEA 
(100 ng/ml, 10 ng/ml, or 1 nglml), T lymphocytes alone (A), non-IFN-?treated synoviocytes alone (B), and 
IFN- ytreated synoviocytes alone (C) did not proliferate, as compared with non-IFN- ytreated synoviocytes 
and T cells with SEA (D), or the maximal T lymphocyte response observed with IFN-?treated synoviocytes 
and SEA (E). b, Effect of the ratio of T lymphocytes to synoviocytes on the SEA response. Synoviocytes at 
4.0 x lo4, 2.0 x lo', 1.0 x lo4, 0.5 x lo4, and 0.1 X lo4 were incubated with 5.0 x lo4 purified T lymphocytes. 
Optimal T lymphocyte response was seen with a ratio of 0.5 X lo4 synoviocytes to 5 X 104 T lymphocytes. 
Values are the mean and SD. 
stimulation were found on the surface of synoviocytes and CD14 (MO-2) were found at low levels (results not 
in culture. CD106 (VCAM-l), CD98, and J4-81/ shown). In contrast, CDSO (B7-BBl), CD86 (B7-2), 
ALCAM (a putative ligand for CD6), were found at and the MHC class I1 molecule were generally not 
high densities (Table I),  while CDIlb/CD18 (MO-1) detectable (Table I). The level of expression of CD54 
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(ICAM-1) and CD58 (LFA-3) varied according to the 
extent of passage in vitro. 
Synoviocytes were treated with 1 ,OOO units/ml 
of IFNy for 48-72 hours to induce MHC class I1 
expression as described by Burmester et a1 (17). 
IFN ytreated synoviocytes were screened by FACS to 
examine whether any additional surface molecules 
were positively or negatively modulated on these cells. 
The expression of CD8O (B7-l), CD86 (B7-2), and 
CD98 did not change with IFNy treatment. The ex- 
pression of CD54 (ICAM-I), CD58 (LFA-3), CDIM 
(VCAM-l), and MHC class I1 was significantly up- 
regulated (Table 1). CD14 (M02) and CD1 lb/CD18 
(M01) were expressed on a subset of cells at passages 
4-6, but were undetectable or present on a much 
smaller number of cells in later passages (data not 
shown). CD50 (ICAM-3) and CD102 (ICAM-2) were 
absent or expressed at very low levels, with or without 
IFN y treatment (data not shown). 
SAg promotion of T lymphocyte binding to syno- 
viocytes. We examined whether SAg affects the ability 
of peripheral blood T lymphocytes to adhere to type B 
synoviocytes (Figure 1). RA type B IFNytreated 
synoviocytes bound small numbers of peripheral blood 
T lymphocytes without SEA (Figure 1). However, 
when SEA was added, the synoviocytes bound T cells 
at a much higher density, as measured by phase- 
contrast microscopy (Figure 1). Enumeration of T 
cells bound per high power field revealed that I F N y  
treated synoviocytes bound 3.5 times the number of T 
cells in the presence of SEA compared with binding in 
the absence of SEA. 
Synoviocyte support of the SEA response. To 
investigate the ability of synoviocytes to support the 
SEA response, IFN ytreated and non-IFN ytreated 
synoviocytes were cocultured with highly purified 
allogeneic resting T cells. Proliferation experiments 
showed that, in the presence of SEA, synoviocytes 
induced T cell activation and proliferation (Figure 2a). 
The T cell response was SEA dosedependent, with 10 
ng/ml or 100 ng/ml SEA stimulating a greater T cell 
response than 1 ng/ml. The optimal response was 
found using 5,000 synoviocytes and 50,000 T cells 
(Figure 2b). Highly purified T cells did not proliferate 
in the presence of SEA, confirming the absence of 
antigen-presenting cells and the purity of the T cells 
(Figure 2a). In addition, synoviocytes alone, with or 
without SEA, and synoviocytes with T cells but no 
SEA, demonstrated negligible proliferation (Figure 
2a). Thus, direct mitogenic effects on synoviocytes 
OKT3 (1 ng/ml) 
PHA 
SEB 
Non-IFN-y treated Synoviocytes 
IFN-y treated Synoviocytes 
1 Pg/mU 
5: 1 T ce1ls:E- 
1 Tcells alone 
0 25000 75000 
[3H]-TdR (cpm) 
Figure 3. Synoviocyte support of both superantigen- and lectin-induced T lymphocyte proliferation. Purified T lymphocytes (5.0 x J04) were 
stimulated with SEB (10 &d), phytohemagglutinin (PHA; 1 pglml), or OKT3 (1500) in the presence of synoviocytes (1.0 x 10") (either 
non-IFN-?treated or IFN- ytreated) and [3H]-TdR incorporation was measured. T lymphocytes (5.0 x 10") mixed with peripheral blood E- 
(1.0 X 10') cells as antigen-presenting cells were used as a positive control. Values are the mean kSD. See Figure 2 for other definitions. 
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Figure 4. Failure of supernatants from rheumatoid arthritis synoviocytes incubated with SEA to induce T 
cell proliferation. IFN-ytreated and non-IFN-ytreated synoviocytes were preincubated with SEA (100 
ng/ml) for 12 hours, 18 hours, or 24 hours before the addition of the supernatants to T lymphocytes. 
Synoviocytes (5.0 x 10’) were plated in 24-well plates and incubated with 1 ml of media alone or 
supplemented with 100 ng/ml SEA. Supernatants at 150 pl were added to 5.0 x lo4 T lymphocytes, which 
were placed in %well round-bottomed plates. Cells were harvested 4 days later, after an 18-hour pulse with 
[3H]-TdR. Proliferation was measured by [3H]-TdR incorporation. The 2 bars on the right show the results 
from cultures that contained both T cells and synoviocytes (syn), and demonstrate responsiveness of the T 
cell population to SEA presented directly by the synoviocytes. Values are the mean and SD. See Figure 2 for 
other definitions. 
and allogeneic responses of the T cells could not 
explain the proliferative responses. 
Synoviocyte support of other SAg and lectin 
responses. Studies were performed to test whether 
synoviocytes, acting as accessory cells, could support 
additional T cell responses. SEB (10 pg/ml), PHA 
(1 pg/ml), and MAb OKT3 (1 500) in combination with 
synoviocytes and T cells were used in proliferation 
assays. SEB and PHA stimulated T cells to proliferate 
with both the IFN ytreated and non-IFN ytreated 
synoviocytes. In contrast, soluble OKT3 did not in- 
duce a response (Figure 3), except when peripheral 
blood antigen-presenting cells were cocultured with 
T cells. 
Necessity of cell contact for synoviocyte support 
of SAg responses by T cells. To test whether cytokines 
secreted by synoviocytes in the presence of SEA 
could independently induce T cell proliferation, both 
IFN ytreated and the non-IFN ytreated synoviocytes 
were incubated with SEA for 12, 18, or 24 hours. The 
supernatants from these cultures were added to highly 
purified T cells. After 72 hours, T cells in culture with 
the supernatants demonstrated no proliferative re- 
sponse (Figure 4). 
Ligand-receptor interactions involved in 
synoviocyte-mediated SAg response. To identify the 
accessory molecules necessary for the observed T cell 
responses, cells were incubated with SEA and MAb 
against CD2, CDlldCD18 (LFA-I), MHC class 11, 
CD58, or CD98. When high concentrations of purified 
MAb (10 pg/ml) were used, marked inhibition of 
proliferative responses was observed (Figure 5) .  Less 
complete inhibition was obtained at lower antibody 
concentrations (data not shown). Inhibition of T cell 
proliferation by MAb to CD98 and CD58 was negligi- 
ble (data not shown). 
Failure of IL-l/3, IL-6, TNFa; and IL-8 to 
independently mediate the T cell-synoviocyte response 
to SAg. We tested whether neutralizing monoclonal 
antibodies to the cytokines IFNy, IL-lp, IL-2, IL-6, 
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Figure 5. Effects of antibodies to cell surface molecules on T lymphocyte responses. Antibodies against 
major histocompatibility complex (MHC) class 11, lymphocyte function-associated antigen 1 (LFA- I) ,  or 
CD2 (10 &ml) were used to block accessory cell function of synoviocytes for T cell responses to SEA (100 
ng/ml, 10 nglml, or 1 ng/ml). Purified T lymphocytes (5.0 x lo4) were incubated with synoviocytes (1 .O x lo4) 
in S w e l l  round-bottomed plates at a final volume of 200 4. Isotype-matched control reagents, for which no 
blocking of T cell responses was observed, included monoclonal antibodies directed against CD6 and CD98 
(data not shown). Values are the mean "SD. MsIg = nonspecific mouse Ig. See Figure 2 for other definitions. 
TNFa, ant L-8 could interrupt the signaling between DISCUSSION 
synoviocytes and T cells. Both IFNytreated and 
non-IFN ytreated cells were incubated with SEA and 
purified T cells, along with MAb to these cytokines. 
Except for anti-IL-2, the anticytokine MAb did not 
have any inhibitory effect on T cell proliferative re- 
sponses in these experiments (Figure 6). 
The present studies demonstrate that cultured 
type B fibroblastic synoviocytes from patients with RA 
can function as accessory cells for T lymphocyte 
responses to superantigen and lectin. The conclusion 
that synoviocytes, and not a contaminating antigen- 
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Figure 6. Effects of anticytokine antibodies. Antibodies to IFN-y, 
interleukin-lp(IL-l/3), IL-2, IL-6, IL-8, and tumor necrosis factor a 
(TNFa) (10 d m l )  were incubated with purified T lymphocytes (5.0 
X lo4) and synoviocytes (1.0 X 104) in %-well round-bottomed 
plates at a final volume of 200 pl in the presence or absence of SEA 
(100 nghl) .  The anti-TNFa antibody is a murine monoclonal 
reagent. Identical results were obtained with a chimeric murine/ 
human anti-TNF antibody known to neutralize TNF function in vivo 
(data not shown). Additional control reagents which had no func- 
tional effects in this system included mouse IgG and a monoclonal 
mouse anti-human von Willebrand factor antibody (results not 
shown). Values are the mean C SD. See Figure 2 for other 
definitions. 
presenting cell population such as synovial mono- 
cytes, provided the observed accessory function is 
supported by several lines of evidence. First, excellent 
accessory cell function was seen with late-passage 
cultures (passages 10-12), at which time no monocytes 
or negligible numbers of monocytes are detectable 
using flow cytometric analysis of surface markers. 
Excellent responses were observed with 5,000 cells 
per well, such that the absolute numbers of contami- 
nating cells would be very low. Furthermore, acces- 
sory cell function was actually more potent with later, 
rather than earlier, passages of the same synoviocyte 
lines, with an inverse correlation between the percent- 
age of cells with monocyte surface markers present 
and the strength of the responses to superantigen or 
lectin upon coculture with T lymphocytes (Diaz L, 
Fox D: unpublished data). Finally, in most of the 
experiments, the T cell response to allogeneic syno- 
viocytes was no greater than a few hundred counts per 
minute above background (occasionally slightly 
higher, as in Figure 3), inconsistent with the presence 
of substantial numbers of professional antigen- 
presenting cells, which are typically excellent stimu- 
lators of allogeneic responses, Poor allostimulatory 
capacity of mixed synoviocyte populations has been 
observed previously (30). The T cell populations used 
were sufficiently depleted of accessory cell popula- 
tions such that they could not respond to superantigen 
or anti-CD3, although partial responses to PHA were 
sometimes seen (Figure 3). 
Consistent with this evidence for low levels of 
contamination by professional antigen-presenting cells 
was the absence of significant levels of MHC class I1 
expression on synoviocytes unless these cells were 
cultured with IFNy. Other published studies have 
shown that a variety of important cell interaction 
molecules, including MHC class 11, ICAM-I (CD54), 
and VCAM-1 (CD106), are inducible on synoviocytes 
with' IFNy, and such molecules have been detected in 
vivo and implicated in the pathogenesis of RA (3 1). An 
interesting finding in the present studies was that IFNy 
was not necessary for accessory cell function of syno- 
viocytes, although it boosted such function in most 
experiments. A spectrum of results was obtained, 
ranging from minimal but clearly detectable accessory 
cell function in the absence of IFNy (Figure 2a) to 
modest augmentation of accessory cell function fol- 
lowing treatment with IFNy (Figure 5) to equivalent 
accessory cell function in the presence and absence of 
IFN y (Figure 3). 
The observation that synoviocytes can present 
superantigen in the absence of baseline MHC class I1 
expression detectable by flow cytometric analysis sug- 
gests several potential explanations. One possibility is 
that synoviocyte molecules other than MHC class I1 
are responsible for presenting superantigen, as has 
been suggested in other experimental systems (32,33). 
Alternatively, MHC class 11 molecules may be ex- 
pressed at functionally significant levels by synovio- 
cytes, but at a surface density too low to be detected 
by flow cytometry. Finally, it is plausible that MHC 
class I1 is significantly up-regulated on synoviocytes 
early during coculture with T cells, facilitating presen- 
tation of superantigen. In support of either or both of 
these latter 2 possibilities, antibody against MHC class 
I1 effectively blocked superantigen presentation (Fig- 
ure 5). In other experiments (results not shown), lower 
concentrations of anti-MHC class I1 more effectively 
blocked antigen presentation by non-IFN ?pretreated 
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cells compared with IFN ypretreated synoviocytes. 
These results are consistent with functionally relevant 
low-level MHC class I1 expression on non-IFNy 
pretreated synoviocytes. It appears likely that func- 
tional assays using blocking effects of antibodies are 
more sensitive for demonstrating a role of MHC class 
11 in these experiments than is baseline flow cytomet- 
ric staining. 
The foregoing considerations suggest that in 
experiments in which IFN y boosted accessory cell 
function of synoviocytes, superinduction of expres- 
sion of MHC class I1 antigens might not necessarily be 
the principal reason for the observed functional 
changes. A variety of other accessory cell surface 
molecules may serve as costimulatory ligands for T 
cell surface structures in the response to superantigen, 
as in other T cell responses. The role of specific 
costimulatory structures in SAg responses may be 
complex, with distinct effects on transcription and 
secretion of various T cell cytokines (34). RA type B 
synoviocytes express ICAM-1 in vivo, but ICAM-2 
and ICAM-3 are expressed only on endothelial cells 
and leukocytes in synovium (31,35). This distinction 
appears to be maintained in vitro on type B synovio- 
cytes. CD28 ligands are absent on or barely expressed 
by type B synoviocytes (Table 1). The role of these 
molecules in T cell proliferative responses to SAg is 
controversial (36-38), but interaction of CD28 with its 
ligands may be involved in SAg-triggered T cell-B cell 
cooperation (39). 
In order to determine the necessary costimula- 
tory receptors and ligands for T cell responses to SAg 
presented by synoviocytes, antibodies were used in 
blocking experiments. When used at high concentra- 
tions (10 pg/ml), purified antibodies directed at LFA-1 
(CD1 ldCD18) and CD2 strongly inhibited superanti- 
gen responses of T lymphocytes in the presence of 
either IFN ypretreated or untreated synoviocytes. In 
other experiments (results not shown), lower concen- 
trations of antibody showed more variable inhibitory 
effects, and inhibition was less effective with IFNy 
pretreated synoviocytes. Such results are compatible 
with higher expression of costimulatory ligands for 
CD2 and LFA-1 on IFNytreated synoviocytes, such 
that blocking effects of monoclonal antibodies are 
difficult to obtain at lower antibody concentrations. 
Consistent with this interpretation was the finding that 
expression of CD54 and CD58, ligands for LFA-I and 
CD2, respectively, were up-regulated with IFN y 
treatment. Even when a majority of cells expressed 
these molecules at baseline, surface density was in- 
creased following exposure to IFN y. 
It was noted that anti-CD58 did not block T cell 
responses despite blocking effects of anti-CD2. This 
may indicate insufficient affinity of the anti-CD58 
reagent, or alternatively, may suggest that anti-CD2 
has effects on T cell function other than inhibition of 
CD58 binding. These could include inhibition of bind- 
ing to other CD2 ligands or direct regulatory signals 
generated through CD2. Anti-CD98 antibody did not 
block T cell proliferation in response to SEA pre- 
sented by IFN ytreated or non-IFN ytreated synovio- 
cytes. However, it has been demonstrated to block the 
T cell response to SEA with PBMC acting as antigen- 
presenting cells (40). These discrepancies are probably 
due to differences in the antigen-presenting cell popu- 
lations used in these 2 systems. 
Effects of antibodies directed at cell-cell inter- 
action structures suggest that the observed T cell 
responses required cell-cell contact, not merely fac- 
tors secreted by accessory cells. Considerable binding 
of T cells to synoviocytes was observed, particularly 
in the presence of superantigen (Figure 1). Since 
superantigen-stimulated synoviocytes have been 
found to secrete cytokines such as IL-6 and IL-8 (22), 
it was important to establish that supernatants of 
superantigen-treated synoviocytes could not by them- 
selves support T cell proliferation, and this was dem- 
onstrated by the data shown in Figure 4. These data do 
not, however, exclude an important role for cytokines 
in costimulating the observed T cell responses, and 
effects of anticytokine monoclonal antibodies were 
therefore investigated. Individual antibodies to IFN y, 
IL-lp, IL-6, IL-8, and TNFa did not down-regulate 
synoviocyte/SEA-induced T cell proliferation. These 
results must be interpreted with caution, however. 
Although the antibodies were selected because of 
documented neutralizing properties (refs. 41 and 42, 
and manufacturers’ data), massive antibody concen- 
trations might be needed to block the responses exam- 
ined in this study. If membrane-bound cytokines play 
a role in regions of close cell contact, antibody block- 
ing might be inefficient. Further studies using combi- 
nations of antibodies seem warranted. A blocking 
antibody directed at human IL-2 did inhibit T cell 
proliferation significantly, consistent with an IL-2/IL-2 
receptor-dependent T cell activation pathway trig- 
gered by superantigen presented by synoviocytes. 
Although type B fibroblastic synoviocytes were 
potent accessory cells for T cell responses to superan- 
tigen and lectin, such cells may not exhibit a full 
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spectrum of accessory cell functions. Thus, responses 
to anti-CD3 antibody were not well supported by 
synoviocyres, possibly relating to poor expression of 
Fc receptors on these cells or a requirement for CD28 
ligands on accessory cells for this response. A recent 
study has suggested that synoviocytes can play a role 
in autologous presentation to T cells of a nominal 
antigen, tetanus toxoid, which is MHC class I1 re- 
stricted (43). Furthermore, synoviocytes were able to 
function as antigen-presenting cells for T cell clones 
specific for mycobacterial antigens, also in an MHC 
class 11-restricted system (43). However, the prolifer- 
ative responses observed were relatively modest. In 
contrast, strong proliferative responses were observed 
in the present studies with low SAg concentrations, 
comparable with SAg responses supported by profes- 
sional antigen-presenting cells, and in contrast to 
responses supported by the murine fibroblast L cell 
line transfected with MHC class I1 molecules, which 
require much higher SAg concentrations (37). 
Synoviocytes are not necessarily the only type 
of fibroblastic cell capable of functioning in antigen 
presentation. A recent report documents the capacity 
of fibroblasts transfected with viral proteins to induce 
antiviral cytotoxic T lymphocyte responses indepen- 
dent of other professional antigen-presenting cells, but 
only in the environment of lymphoid organs (44). In 
this regard, our findings with RA type B synoviocytes 
could be relevant to cell-cell interactions in vivo, 
given the histologic resemblance of RA synovial in- 
flammation to lymphoid tissue in patients with active 
disease. 
A role for superantigens in the pathogenesis of 
RA would depend on the functional properties of 
accessory cells found in the synovium (and possibly 
elsewhere) and on the responses of T lymphocytes to 
such antigens. Some recent reports have suggested 
that the Vp repertoire in RA reflects SAg responses 
(23,24), but other studies have yielded somewhat 
contradictory results (45,46). No reports, to our 
knowledge, have documented the ability of synovial 
tissue cells to present SAg to T lymphocytes. 
Superantigens have been implicated in various 
infectious diseases due to staphylococci and mycobac- 
teria (47,48). Endogenous superantigens have been 
identified in mice (for review, see ref. 49) but not yet in 
humans. In animal models, SAg responses can initiate 
joint inflammation (50) or exacerbate autoimmune 
responses in the synovium (51) or in the central 
nervous system (52,53). If SAg have a role in auto- 
immune diseases with organ-specific manifestations, 
SAg presentation by cells localized to such organs 
could be important. Pertinent findings in this regard 
include the recent demonstration that keratinocytes 
can present SAg in an LFA- l/ICAM-Mependent 
manner (5435) and a report of SAg presentation by 
intestinal epithelial cells (56). Dendritic cells localized 
to the skin (57), the joint (58), or other tissues could 
also be important in localized SAg presentation. Re- 
cently, evidence for a SAg effect on lymphocytes 
infiltrating the pancreas in early type I diabetes has 
been described (59). 
The data in this report demonstrate that cul- 
tured rheumatoid type B fibroblast-like synoviocytes 
are capable of supporting T lymphocyte proliferation 
in response to SAg and lectin. This system, while not 
establishing a role for SAg in RA, provides a new and 
useful model for examining synoviocyte-T cell inter- 
actions in induction of T cell responses that could 
contribute to the pathogenesis of this disease. These 
findings, together with evidence that RA type B syno- 
viocytes can support differentiation of B cells into 
plasma cells (60), begin to define a role for synovio- 
cytes in the induction of immune responses. 
Addendum. A recent report by Kraft and colleagues 
(61) also documents accessory cell function of synovial 
fibroblasts in T cell responses to superantigen. 
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